Bio-View Ltd Cash Flow Conversion Efficiency
Bio-View Ltd cash flow conversion efficiency. Based on the latest financial reports, Bio-View Ltd (BIOV) has a cash flow conversion efficiency ratio of 0.049x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA1.38 Million ≈ $3.70K USD) by net assets (ILA28.28 Million ≈ $75.81K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bio-View Ltd (2009–2024)
Cash flow conversion efficiency of Bio-View Ltd from 2009 to 2024. This chart illustrates how Bio-View Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BIOV stock price and chart for real-time trading data and today's change.
Bio-View Ltd Cash Flow Conversion Ratio Explained
Bio-View Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bio-View Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bio-View Ltd ranked by their cash flow conversion efficiency. Also see BIOV market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mostostal Warszawa S.A.
WAR:MSW
|
1.170x |
|
Perpetuals.com Ltd
NASDAQ:PDC
|
-0.341x |
|
S&K Polytec Co. Ltd
KQ:091340
|
0.133x |
|
Flexiroam Ltd
AU:FRX
|
-0.898x |
|
Diagnos Laboratorium Utama PT Tbk
JK:DGNS
|
0.008x |
|
Mgenplus Co. Ltd.
KQ:032790
|
-0.049x |
|
Bankers Investment Trust
LSE:BNKR
|
0.029x |
|
JPEL Private Equity Ltd
LSE:JPEL
|
0.023x |
Annual Cash Flow Conversion Efficiency for Bio-View Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Bio-View Ltd from 2009 to 2024. Review cash generation quality of Bio-View Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA22.95 Million ≈ $61.52K |
ILA-3.11 Million ≈ $-8.33K |
-0.135x | -2515.71% |
| 2023-12-31 | ILA27.30 Million ≈ $73.20K |
ILA153.00K ≈ $410.19 |
0.006x | -83.63% |
| 2022-12-31 | ILA28.28 Million ≈ $75.81K |
ILA968.00K ≈ $2.60K |
0.034x | -71.36% |
| 2021-12-31 | ILA27.16 Million ≈ $72.82K |
ILA3.25 Million ≈ $8.71K |
0.120x | +273.69% |
| 2020-12-31 | ILA25.07 Million ≈ $67.21K |
ILA802.00K ≈ $2.15K |
0.032x | -68.02% |
| 2019-12-31 | ILA24.95 Million ≈ $66.89K |
ILA2.50 Million ≈ $6.69K |
0.100x | +271.76% |
| 2018-12-31 | ILA22.75 Million ≈ $60.99K |
ILA-1.32 Million ≈ $-3.55K |
-0.058x | -2629.85% |
| 2017-12-31 | ILA23.45 Million ≈ $62.88K |
ILA54.00K ≈ $144.77 |
0.002x | -98.29% |
| 2016-12-31 | ILA27.61 Million ≈ $74.01K |
ILA3.73 Million ≈ $9.99K |
0.135x | -33.43% |
| 2015-12-31 | ILA22.99 Million ≈ $61.63K |
ILA4.66 Million ≈ $12.50K |
0.203x | +12.52% |
| 2014-12-31 | ILA18.18 Million ≈ $48.75K |
ILA3.28 Million ≈ $8.79K |
0.180x | +196.72% |
| 2013-12-31 | ILA15.65 Million ≈ $41.95K |
ILA-2.92 Million ≈ $-7.82K |
-0.186x | -232.37% |
| 2012-12-31 | ILA16.69 Million ≈ $44.76K |
ILA2.35 Million ≈ $6.30K |
0.141x | -34.69% |
| 2011-12-31 | ILA15.20 Million ≈ $40.75K |
ILA3.28 Million ≈ $8.78K |
0.216x | -54.61% |
| 2010-12-31 | ILA8.18 Million ≈ $21.92K |
ILA3.88 Million ≈ $10.41K |
0.475x | +935.47% |
| 2009-12-31 | ILA1.55 Million ≈ $4.15K |
ILA71.00K ≈ $190.35 |
0.046x | -- |
About Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more